Moonwalk Biosciences is a relatively new anti-aging biotech company looking to pioneer precision epigenetic medicines to improve longevity.
“Epigenetics is the software of the genome. While changes to the genome are irreversible, edits to the epigenome can be reprogrammed in different ways. Epigenetic changes determine whether genes are turned on or off, and can potentially reverse disease, broadening the therapeutic landscape to find potential cures previously thought impossible”
Alex Aravanis, CEO and Co-Founder, Moonwalk Biosciences
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The Solution
Moonwalk Biosciences is focused on utilizing epigenetic reprogramming to treat diseases, including those related to aging.
Their solution involves reading and writing the epigenome, which is the layer of gene regulation that controls how genes are expressed without changing the underlying DNA. They aim to do this through DNA methylation, otherwise known as gene silencing, and they are also developing technologies for other epigenomic modifications involving histones.
By modifying specific epigenetic markers, they aim to reverse harmful changes that accumulate with age and cause various diseases.
Their platform uses advanced machine learning and AI tools to identify and target these epigenetic changes. The ultimate goal is to restore cells to a youthful, healthy state, potentially reversing or mitigating the effects of disease and aging.
The following image from their official website provides an illustration of the solution, or the technology in action as the company refers to it:
Unfortunately, the company has yet to reveal an official pipeline, but hopefully we will hear more updates on their developments soon.
The Company
Moonwalk Biosciences was established in 2022, and has its headquarters in San Francisco, CA, USA. The company was co-founded by Feng Zhang, Arash Jamshidi, Justin Valley, and Alex Aravanis who is also the CEO of the company.
In January of 2024 the company announced the completion of a series A seed funding round of $57 million led by Alpha Wave Ventures, and joined by other leading life sciences investors such as ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures. This initial round of financing will support the continued development of their epigenetic technology platform with the aim of progressing their undisclosed pipeline of epigenetic therapeutics towards the clinic.
Read about more anti-aging companies on this website through this link.
